Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07373639 · ClinicalTrials.gov registry record

A Long-term Follow-up Study in Patients Who Received BEAM-101

A clinical trial of Sickle Cell Disease and Hemoglobinopathy, sponsored by Beam Therapeutics.

Recruiting
Registry status
50
Enrollment target
17
Study locations

NCT07373639 is a study of Sickle Cell Disease and Hemoglobinopathy that is actively recruiting participants, run by Beam Therapeutics. The registered enrollment target is 50 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (83% lower). The trial reports 17 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07373639, a study of Sickle Cell Disease and Hemoglobinopathy, is actively recruiting participants, sponsored by Beam Therapeutics.

RECRUITING
Registry status
50 participants
Enrollment target
17
Study locations

Study Summary

This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).

Conditions Studied

Sickle Cell Disease Hemoglobinopathy

Interventions

  • DRUG Long-Term Follow-up Study of patients who received BEAM-101

Study Locations (17)

Ohio

  • University Hospitals Clevland Medical Center - Cleveland
  • The Clevland Clinic Foundation - Cleveland

Tennessee

  • St. Jude Children's Research Hospital - Memphis
  • The Children's Hospital at TriStar Centennial - Nashville

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Phoenix Children's Hospital - Phoenix

Florida

  • Mayo Clinic Florida - Jacksonville

Georgia

  • Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston - Atlanta

Massachusetts

  • Boston Children's Hospital - Boston

Michigan

  • Henry Ford Cancer Center - Detroit

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-12-15
Est. Completion 2043-02-12

Sponsor

Beam Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07373639

The ClinicalTrials.gov registry entry for NCT07373639 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (83% lower). The listed sponsor is Beam Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Long-Term Follow-up Study of patients who received BEAM-101 is the first listed.

NCT07373639 reports 17 study locations spanning 15 distinct geographic areas - top geographies include Ohio, Tennessee, Alabama.

Frequently Asked Questions

What is clinical trial NCT07373639 about?

NCT07373639 is a clinical study titled "A Long-term Follow-up Study in Patients Who Received BEAM-101". This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for...

What is the current status of trial NCT07373639?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-12-15. Estimated completion is 2043-02-12.

What conditions does trial NCT07373639 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Hemoglobinopathy.

What interventions are being tested in trial NCT07373639?

The interventions under investigation include: Long-Term Follow-up Study of patients who received BEAM-101 (DRUG).

Who is sponsoring clinical trial NCT07373639?

This trial is sponsored by Beam Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07373639 being conducted?

This trial has 17 study locations across Alabama, Arizona, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Hemoglobinopathy

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.